Stocks · News reference
RBC Capital Markets increased its price target for Aurinia Pharmaceuticals Inc. from $16 to $18 while maintaining a 'Sector Perform' rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aurinia Pharmaceuticals Inc. announced its financial results for the third quarter of 2026, reporting total revenue of $83.7 million, a 14% increase compared to the same period in 2025.
Filed: 2026-10-30 AccNo: 0001600620-26-000074 Size: 344 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.